Correction: Tumor-restricted activation of Vγ9Vδ2 T cells via bispecific Evobodies: a novel strategy for safe and potent immunotherapy in ovarian cancer

Affiliations

¹ Institute of Immunology, University Hospital Schleswig-Holstein, Kiel, Germany.
² Evobright GmbH, Vienna, Austria.
³ Division of Antibody-Based Immunotherapy, University Hospital Schleswig-Holstein and Christian-Albrechts University, Kiel, Germany.
⁴ Polyclinic and Clinic of Gynecology, University Center, Jena, Germany.

^# Contributed equally.

Published Erratum

Hans-Heinrich Oberg et al. Front Immunol. 2025.

. 2025 Sep 12:16:1672018.

doi: 10.3389/fimmu.2025.1672018. eCollection 2025.

¹ Institute of Immunology, University Hospital Schleswig-Holstein, Kiel, Germany.
² Evobright GmbH, Vienna, Austria.
³ Division of Antibody-Based Immunotherapy, University Hospital Schleswig-Holstein and Christian-Albrechts University, Kiel, Germany.
⁴ Polyclinic and Clinic of Gynecology, University Center, Jena, Germany.

^# Contributed equally.

Abstract

[This corrects the article DOI: 10.3389/fimmu.2025.1628501.].

Keywords: BTN3A; FOLR1; Vγ9Vδ2 T cells; evobody; immunotherapy; ovarian cancer.

Tumor-restricted activation of Vγ9Vδ2 T cells via bispecific Evobodies: a novel strategy for safe and potent immunotherapy in ovarian cancer.
Oberg HH, Deseke M, Krohn S, Winterberg D, Peipp M, Bauerschlag D, Künkele KP, Wesch D, Baumann C. Oberg HH, et al. Front Immunol. 2025 Jul 18;16:1628501. doi: 10.3389/fimmu.2025.1628501. eCollection 2025. Front Immunol. 2025. PMID: 40755782 Free PMC article.